Eli Lilly has announced that starting July 7, 2025, the highest approved doses of its weight-loss drug Zepbound—12.5 mg and 15 mg—will be available in single-dose vials at a price of \$499 per month through LillyDirect’s Self Pay Pharmacy Solutions. This move means that all doses of Zepbound will now be accessible for \$499 per month or less, with the starter dose priced at \$349, regardless of patients’ insurance coverage.
Zepbound is approved for adults who are obese or overweight and have weight-related health conditions. In clinical trials, the 15 mg dose demonstrated impressive results. On average, adults taking this dose lost about 48 pounds, which amounts to roughly 21% of their body weight. Additionally, about one-third of patients lost more than 58 pounds, or 25% of their weight. The drug’s full dosing range includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg options. Prices for these doses under the Self Pay Journey Program typically range from \$349 to \$1,049, but with program benefits, the cost is capped at \$499 per month.
Zepbound has shown significant effectiveness in both people with and without diabetes. Eli Lilly’s pricing adjustment aims to make the medication more affordable and accessible to a wider range of patients seeking weight management solutions, regardless of their insurance status.
Related Topics:
Vitamin Gummies Recalled Over Undeclared Peanut Allergen
